Virological and immunological response to three boosted protease inhibitor regimens
© Baumgardt et al; licensee BioMed Central Ltd. 2008
Published: 10 November 2008
Purpose of the study
To compare the virological, immunological and clinical response to three boosted double protease inhibitor (PI) regimens of saquinavir and ritonavir in combination with lopinavir (LOPSAQ), atazanavir (ATSAQ) or fosamprenavir (FOSAQ) without reverse transcriptase inhibitors (RTI) in HIV-positive patients with limited RTI treatment options.
Comparative cohort observation of pre-treated patients (n = 279) who had experienced therapy failure on their RTI-regimen due to resistance and/or toxicity. Patients with PI-resistance mutations or RTI toxicity underwent a structured treatment interruption until virus reverted to wild-type or resolution of toxicity symptoms.
Summary of results
The virologic response to treatment was similar in between the three combinations of LOPSAQ, ATSAQ or FOSAQ, respectively. This RTI-sparing, PI-only antiretroviral therapy may be an effective option for treatment experienced patients after RTI-failure due to toxicity or resistance. The immunological outcome of both LOPSAQ and ATSAQ seems to be superior to FOSAQ. For extensively pre-treated patients at low CD cell counts, this historical option of a double-PI only combination regimen is today extended by new antiretroviral classes.
This article is published under license to BioMed Central Ltd.